An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments for acute myeloid leukaemia (AML).
The protein, YTHDF2, is needed in order to trigger and sustain the fatal form of blood cancer. However YTHDF2 is not needed for healthy cells to function.
As such YTHDF2 could be a promising target for drug treatments of leukaemia.
Original Article: Researchers find Achilles' heel protein in leukaemia